Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1986 Apr;53(4):561–566. doi: 10.1038/bjc.1986.88

Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.

R Ganapathi, A Yen, D Grabowski, H Schmidt, R Turinic, R Valenzuela
PMCID: PMC2001449  PMID: 3707847

Full text

PDF
561

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chafouleas J. G., Bolton W. E., Hidaka H., Boyd A. E., 3rd, Means A. R. Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression. Cell. 1982 Jan;28(1):41–50. doi: 10.1016/0092-8674(82)90373-7. [DOI] [PubMed] [Google Scholar]
  2. Chang B. K., Gregory J. A. Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer. Cancer Chemother Pharmacol. 1985;14(2):132–134. doi: 10.1007/BF00434351. [DOI] [PubMed] [Google Scholar]
  3. Ganapathi R., Grabowski D. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 1983 Aug;43(8):3696–3699. [PubMed] [Google Scholar]
  4. Ganapathi R., Grabowski D., Schmidt H., Seshadri R., Israel M. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells. Biochem Biophys Res Commun. 1985 Sep 16;131(2):912–919. doi: 10.1016/0006-291x(85)91326-9. [DOI] [PubMed] [Google Scholar]
  5. Ganapathi R., Grabowski D., Turinic R., Valenzuela R. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells. Eur J Cancer Clin Oncol. 1984 Jun;20(6):799–806. doi: 10.1016/0277-5379(84)90219-0. [DOI] [PubMed] [Google Scholar]
  6. Ganapathi R., Gulick P., Miller R., Grabowski D., Turinic R., Valeunzuela R., Fishleder A., Bukowski R. Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry. Invest New Drugs. 1985;3(3):273–277. doi: 10.1007/BF00179431. [DOI] [PubMed] [Google Scholar]
  7. Inaba M., Johnson R. K. Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. Biochem Pharmacol. 1978;27(17):2123–2130. doi: 10.1016/0006-2952(78)90284-8. [DOI] [PubMed] [Google Scholar]
  8. Inaba M., Kobayashi H., Sakurai Y., Johnson R. K. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979 Jun;39(6 Pt 1):2200–2203. [PubMed] [Google Scholar]
  9. Kartner N., Shales M., Riordan J. R., Ling V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res. 1983 Sep;43(9):4413–4419. [PubMed] [Google Scholar]
  10. Kessel D., Wilberding C. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res. 1985 Apr;45(4):1687–1691. [PubMed] [Google Scholar]
  11. Krishan A., Frei E., 3rd Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res. 1976 Jan;36(1):143–150. [PubMed] [Google Scholar]
  12. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975 Jul;66(1):188–193. doi: 10.1083/jcb.66.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Riehm H., Biedler J. L. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res. 1972 Jun;32(6):1195–1200. [PubMed] [Google Scholar]
  14. Skovsgaard T. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor. Cancer Res. 1980 Apr;40(4):1077–1083. [PubMed] [Google Scholar]
  15. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 1978 Jun;38(6):1785–1791. [PubMed] [Google Scholar]
  16. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982 Nov;42(11):4730–4733. [PubMed] [Google Scholar]
  17. Wheeler C., Rader R., Kessel D. Membrane alterations associated with progressive adriamycin resistance. Biochem Pharmacol. 1982 Aug 15;31(16):2691–2693. doi: 10.1016/0006-2952(82)90723-7. [DOI] [PubMed] [Google Scholar]
  18. Yen A., Fairchild D. G. T-cell control of B-cell proliferation uncoupled from differentiation. Cell Immunol. 1982 Dec;74(2):269–276. doi: 10.1016/0008-8749(82)90027-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES